NMPA
國家藥品監督管理局
China
Last reviewed 2026-08-05
國家藥監局透過CMDE（醫療器材技術審評中心）進行技術審評來監管醫療器材。中國採用三級風險分類體系。外國製造商必須指定上市許可持有人（MAH），II類和III類器材需完成境內檢測。中國是全球第二大醫療器材市場。
NMPA STRUCTURE AND MARKET IMPORTANCE
NMPA (formerly CFDA) is China’s national authority for medical devices, drugs, and cosmetics. Technical review of higher-risk devices is led by CMDE. China is the world’s second-largest device market, so NMPA strategy often sits beside FDA/EU MDR in multi-market launch plans. Rules evolve quickly around clinical evaluation, unique device identification, and MAH accountability.
REGISTRATION PATHWAY AT A GLANCE
Class I devices generally use filing/notification. Class II and III require registration dossiers, type testing at NMPA-recognized labs, and often clinical evidence depending on catalogue rules. Foreign manufacturers must work through a Chinese Marketing Authorization Holder (MAH) that holds the certificate and post-market duties—unlike FDA clearances that a foreign firm can hold with a US agent model.
TIMELINES AND COMMON BOTTLENECKS
Class II often takes roughly 6–12 months and Class III 12–24+ months after a complete package, with clinical trials adding years when required. Bottlenecks include incomplete Chinese-language documentation, unexpected classification differences vs FDA/EU, and testing queue times. Cross-mapping product codes early reduces rework.
POST-MARKET AND VIGILANCE
After approval, MAHs manage adverse event reporting, re-registration cycles, and manufacturing change notifications. Surveillance actions and standards updates can affect devices already on market. Global RA teams should watch NMPA notices in parallel with FDA recalls and EU FSCA signals for multi-region products.
器材分類
Class I, II, III
審批路徑
NMPA Registration (CMDE review)
核心監管職能
- ▸CMDE技術審評
- ▸MAH（上市許可持有人）制度
- ▸境內檢測要求
- ▸臨床試驗監管
- ▸NMPA註冊證
§ RELATED INTELLIGENCE
§ FAQ
What is NMPA in China?
The NMPA (National Medical Products Administration) is China's national regulatory authority for medical devices, drugs, and cosmetics. Formerly known as CFDA, it oversees device registration, market surveillance, and post-market safety through its technical review body CMDE (Center for Medical Device Evaluation). China is the world's second-largest medical device market.
How do I register a medical device with NMPA?
NMPA registration requires appointing a Marketing Authorization Holder (MAH) in China, completing in-country testing at a NMPA-recognized laboratory for Class II and III devices, submitting a technical dossier to CMDE for review, and obtaining a registration certificate. Foreign manufacturers cannot hold the registration directly — a Chinese MAH entity is mandatory.
What are NMPA medical device classification requirements?
China uses a three-class risk-based system. Class I (lowest risk) requires filing notification with local authorities. Class II (moderate risk) requires registration with provincial-level NMPA. Class III (highest risk) requires registration with national NMPA through CMDE review. Classification is determined by the NMPA Classification Catalogue, which may differ from FDA or EU classifications for the same device.
How long does NMPA medical device approval take?
NMPA approval timelines vary by device class. Class I notification typically takes 1–2 months. Class II registration takes 6–12 months. Class III registration takes 12–24+ months due to CMDE technical review complexity. Clinical trials, if required, can add 1–3 additional years. In-country testing alone typically requires 3–6 months.
Do foreign manufacturers need a local representative for NMPA?
Yes. Foreign manufacturers must appoint a Marketing Authorization Holder (MAH) — a Chinese legal entity responsible for the device registration, post-market surveillance, and regulatory compliance in China. The MAH holds the registration certificate and bears legal responsibility. This is one of the most significant differences from FDA registration, where foreign manufacturers can hold their own clearances through a US Agent.
MedFlux即時監控NMPA的監管變化、安全警報和市場信號——讓您的團隊不錯過任何關鍵更新。
免費監控{abbr} →